Machine learning-enabled identification of nucleus pulposus senescence-associated genes as potential biomarkers for intervertebral disc degeneration
Source check: Source checked. Not independent scientific confirmation.
Finding: Analysis of the GSE70362 gene-expression data identified TAF13 as a candidate nucleus-pulposus senescence-associated marker for intervertebral disc degeneration. Random forest and SVM recursive feature elimination contributed to the selection; qPCR and Western blot in vivo assays, followed by qPCR in human nucleus-pulposus tissue, supported the reported expression pattern. Clinical diagnostic performance or utility was not demonstrated.
Technology: Random forest and SVM recursive feature elimination with co-expression analysis
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Random forest and SVM-RFE prioritized genes associated with disc degeneration; subsequent assays examined the selected TAF13 expression signal.
- Test and result
- The study analyzed expression profiles and used qPCR and Western blot in vivo, plus qPCR in human nucleus-pulposus samples, to assess TAF13 expression. These assays supported the marker’s expression pattern in the reported material.
- Limitation / still unknown
- The biomarker claim is not a demonstration of clinical diagnostic performance or utility in an independent prospective patient cohort; expression associations do not establish causality.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12482253/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.